{
  "trial_id": "NCT00115739",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "histologically confirmed anaplastic thyroid carcinoma",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "measurable disease",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "brain metastases stable for at least six weeks post-radiation therapy",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "age 18 years, male or female",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Karnofsky performance status (KPS) of > 70%",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "life expectancy of at least 12 weeks",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Hematologic: ANC 1,500 mm3, hemoglobin 8.0 g/dl, platelets 100,000/mm3",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Normal serum calcium level within normal limits for the institution documented within 14 days prior to registration",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Adequate hepatic function as defined by a serum bilirubin 1.5 x the institutional upper limit of normal (ULN), and ALT and AST <2.5 x ULN, obtained within 14 days prior to registration",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must have a serum creatinine less than 1.5 x the institutional upper limits of normal (adjusted for age) within 14 days of registration",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Women of childbearing potential must have a negative pregnancy test at baseline, prior to receiving any study drug",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients of reproductive potential must practice effective contraception while on study and for at least six months after receiving the last dose of study drug",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "All patients must sign an informed consent prior to enrollment",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Anaplastic thyroid cancer that does not overexpress PDGF receptors or c-Abl by immunohistochemistry",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Pregnant or lactating women, women of childbearing potential with either a positive pregnancy test (PPT) at baseline, or sexually active females not using reliable contraceptive methods while on study and for at least six months after chemotherapy",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Sexually active males not using reliable contraceptive methods while on the study and for at least six months after chemotherapy",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Patients with malabsorption syndromes will be excluded",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Serious concurrent infections",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Patients who have had previous organ allografts will be excluded",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Prisoners",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients with chronic liver disease (i.e chronic active hepatitis and cirrhosis)",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of anaplastic astrocytoma, which is not eligible for the trial. Additionally, patient's age and Karnofsky performance status are within the inclusion criteria.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT00115739",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}